These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 21264482)
1. Computational analysis of aspartic protease plasmepsin II complexed with EH58 inhibitor: a QM/MM MD study. de Farias Silva N; Lameira J; Alves CN J Mol Model; 2011 Oct; 17(10):2631-8. PubMed ID: 21264482 [TBL] [Abstract][Full Text] [Related]
2. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. Asojo OA; Gulnik SV; Afonina E; Yu B; Ellman JA; Haque TS; Silva AM J Mol Biol; 2003 Mar; 327(1):173-81. PubMed ID: 12614616 [TBL] [Abstract][Full Text] [Related]
3. Flap dynamics of plasmepsin proteases: insight into proposed parameters and molecular dynamics. Karubiu W; Bhakat S; McGillewie L; Soliman ME Mol Biosyst; 2015 Apr; 11(4):1061-6. PubMed ID: 25630418 [TBL] [Abstract][Full Text] [Related]
4. Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370. Asojo OA; Afonina E; Gulnik SV; Yu B; Erickson JW; Randad R; Medjahed D; Silva AM Acta Crystallogr D Biol Crystallogr; 2002 Dec; 58(Pt 12):2001-8. PubMed ID: 12454457 [TBL] [Abstract][Full Text] [Related]
5. The protonation state of the catalytic aspartates in plasmepsin II. Friedman R; Caflisch A FEBS Lett; 2007 Aug; 581(21):4120-4. PubMed ID: 17689534 [TBL] [Abstract][Full Text] [Related]
6. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues. Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050 [TBL] [Abstract][Full Text] [Related]
7. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors. Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996 [TBL] [Abstract][Full Text] [Related]
8. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor. Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991 [TBL] [Abstract][Full Text] [Related]
9. Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors. Recacha R; Leitans J; Akopjana I; Aprupe L; Trapencieris P; Jaudzems K; Jirgensons A; Tars K Acta Crystallogr F Struct Biol Commun; 2015 Dec; 71(Pt 12):1531-9. PubMed ID: 26625296 [TBL] [Abstract][Full Text] [Related]
10. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region. Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224 [TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum. Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205 [TBL] [Abstract][Full Text] [Related]
12. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin]. Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746 [TBL] [Abstract][Full Text] [Related]
13. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes. Hodder AN; Sleebs BE; Czabotar PE; Gazdik M; Xu Y; O'Neill MT; Lopaticki S; Nebl T; Triglia T; Smith BJ; Lowes K; Boddey JA; Cowman AF Nat Struct Mol Biol; 2015 Aug; 22(8):590-6. PubMed ID: 26214367 [TBL] [Abstract][Full Text] [Related]
14. Protein surface roughness accounts for binding free energy of Plasmepsin II-ligand complexes. Valdés-Tresanco ME; Valdés-Tresanco MS; Valiente PA; Cocho G; Mansilla R; Nieto-Villar JM J Mol Recognit; 2018 Jan; 31(1):. PubMed ID: 28895236 [TBL] [Abstract][Full Text] [Related]
15. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D. Dali B; Keita M; Megnassan E; Frecer V; Miertus S Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033 [TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Nezami A; Luque I; Kimura T; Kiso Y; Freire E Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219 [TBL] [Abstract][Full Text] [Related]
17. Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank. Robbins AH; Dunn BM; Agbandje-McKenna M; McKenna R Acta Crystallogr D Biol Crystallogr; 2009 Mar; 65(Pt 3):294-6. PubMed ID: 19237752 [TBL] [Abstract][Full Text] [Related]
18. Calculation of binding free energies of inhibitors to plasmepsin II. Steiner D; Oostenbrink C; Diederich F; Zürcher M; van Gunsteren WF J Comput Chem; 2011 Jul; 32(9):1801-12. PubMed ID: 21488062 [TBL] [Abstract][Full Text] [Related]
19. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Silva AM; Lee AY; Gulnik SV; Maier P; Collins J; Bhat TN; Collins PJ; Cachau RE; Luker KE; Gluzman IY; Francis SE; Oksman A; Goldberg DE; Erickson JW Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10034-9. PubMed ID: 8816746 [TBL] [Abstract][Full Text] [Related]
20. Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein. Luksch T; Blum A; Klee N; Diederich WE; Sotriffer CA; Klebe G ChemMedChem; 2010 Mar; 5(3):443-54. PubMed ID: 20112327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]